Literature DB >> 10748176

Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer.

K Datta1, R Nambudripad, S Pal, M Zhou, H T Cohen, D Mukhopadhyay.   

Abstract

Insulin-like growth factor-I (IGF-I)-mediated signaling is thought to be involved in the regulation of multiple cellular functions in different tumors including renal cell carcinoma (RCC). Blocking IGF-I signaling by any of the several strategies abolishes or delays the progression of a variety of tumors in animal models. Herein, we demonstrate that in RCC cell lines, IGF-I-mediated signaling is found to be inhibited in the presence of wild type von Hippel-Lindau (VHL) tumor suppresser gene. Moreover, molecular modeling and biochemical approaches have revealed that beta-domain of the VHL gene product by interacting directly with protein kinase Cdelta inhibits its association with IGF-IR for downstream signaling. We also demonstrated that RCC has IGF-I-mediated invasive activity where protein kinase Cdelta is an important downstream molecule, and this invasiveness can be blocked by wild type VHL. These experiments thus elucidate a novel tumor suppresser function of VHL with its unique kinase inhibitory domain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10748176     DOI: 10.1074/jbc.M909970199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

Review 2.  Cancer.

Authors:  Adda Grimberg
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

3.  Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.

Authors:  Eijiro Nakamura; Paula Abreu-e-Lima; Yasuo Awakura; Takahiro Inoue; Toshiyuki Kamoto; Osamu Ogawa; Hirokazu Kotani; Toshiaki Manabe; Guo-Jun Zhang; Keiichi Kondo; Vānia Nosé; William G Kaelin
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

4.  VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration.

Authors:  Olga V Razorenova; Elizabeth C Finger; Renata Colavitti; Sophia B Chernikova; Alexander D Boiko; Charles K F Chan; Adam Krieg; Barbara Bedogni; Edward LaGory; Irving L Weissman; Marianne Broome-Powell; Amato J Giaccia
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-13       Impact factor: 11.205

5.  The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase Cdelta.

Authors:  Xavier Iturrioz; Joanne Durgan; Véronique Calleja; Banafshé Larijani; Heiwa Okuda; Richard Whelan; Peter J Parker
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

Review 6.  The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.

Authors:  Volker H Haase
Journal:  Semin Cell Dev Biol       Date:  2005-04-26       Impact factor: 7.727

7.  Bryostatin-1 causes radiosensitization of BMG-1 malignant glioma cells through differential activation of protein kinase-Cδ not evident in the non-malignant AA8 fibroblasts.

Authors:  Raghubendra Singh Dagur; Shashank Hambarde; Sudhir Chandna
Journal:  Mol Cell Biochem       Date:  2014-12-04       Impact factor: 3.396

Review 8.  Mechanisms by which IGF-I may promote cancer.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

Review 9.  The VHL tumor suppressor and HIF: insights from genetic studies in mice.

Authors:  P P Kapitsinou; V H Haase
Journal:  Cell Death Differ       Date:  2008-01-25       Impact factor: 15.828

Review 10.  The VHL tumor suppressor: master regulator of HIF.

Authors:  Volker H Haase
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.